Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion

Breccia, M; Pregno, P; Spallarossa, P; Arboscello, E; Ciceri, F; Giorgi, M; Grossi, A; Mallardo, M; Nodari, S; Ottolini, S; Sala, C; Tortorella, G; Rosti, G; Pane, F; Minotti, G; Baccarani, M

Breccia, M (reprint author), Sapienza Univ Azienda Policlinico Umberto 1, Dept Cellular Biotechnol & Hematol, Rome, Italy.

ANNALS OF HEMATOLOGY, 2017; 96 (4): 549

Abstract

Ponatinib (Iclusig, ARIAD Pharmaceuticals-Incyte Co.) is a third-generation structure-guided tyrosine kinase inhibitor that is approved for treatment ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索